A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer

Inclusion Criteria: * adult patients, \>/=19 years of age * metastatic or unresectable colorectal or ovarian cancer refractory to, or unsuitable for standard therapy * presence of tumor lesions suitable for DCE-MRI evaluation * WHO performance status 0-1 * adequate bone marrow, liver and renal function Exclusion Criteria: * patient unsuitable for MRI scanning (e.g. metal implants, pacemaker, claustrophobia, hypersensitivity to DCE-MRI contrast material) * brain metastases * clinically significant ascites * active bleeding, bleeding diathesis, oral anti-vitamin K medication (other than low dose coumarin) or history of coagulation disorders * radiation therapy within 3 weeks, or anti-neoplastic therapy \<30 days prior to first dose of study drug * chronic therapy with systemic steroids or another immunosuppressive agent \<2 weeks prior to first dose of study drug * treated with bevacizumab in last regimen of systemic therapy